Previous 10 | Next 10 |
Image source: The Motley Fool. Voyager Therapeutics, Inc. (NASDAQ: VYGR) Q3 2019 Earnings Call Nov 6, 2019 , 8:00 a.m. ET Operator Continue reading
The following companies have filed for mixed shelf offerings: More news on: Nephros, Inc., Voyager Therapeutics, Inc., Allogene Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Voyager Therapeutics (NASDAQ: VYGR ): Q3 GAAP EPS of -$0.41 beats by $0.32 . More news on: Voyager Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today reported its third quarter 2019 financial results, program progress and...
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced a management presentation at the following upcoming investor ...
CAMBRIDGE, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it will report its third quarter 2019 financial results ...
CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management presentations at the following upcoming investor ...
Axovant Gene Therapies ( AXGT ) is running three clinical programs on three gene therapy candidates for neurological and developmental disorders. Readouts from all three programs are expected in Q4'19, presenting an opportunity for a trade, which is the focus of this article. A big Q4'19 u...
Investment thesis Interpreting low-dose Cohort 1 data as functionally active strengthens Phase 1b results and bodes well for Phase 2 data. The premise of this investment thesis is that a low-dose placebo effect for a gene-therapy asset held by Voyager Therapeutics (VYGR), a biotech com...
Pixabay Data is the foundation of investing. Most investment focuses on data in the form of earnings per share, PE multiple, revenue growth, PEG ratio, etc. Biotech clinical results are based upon data. This article is a vehicle to present alternative data used to help understand clinical ...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...